New breast cancer trial aims to skip chemo for some patients

NCT ID NCT07616427

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called fovinaciclib combined with hormone therapy and targeted antibodies in people with early-stage HR-positive/HER2-positive breast cancer. After 6 weeks, doctors check if the tumor is shrinking. If it is, patients continue the same treatment; if not, they switch to standard chemotherapy before surgery. The goal is to see if this approach can cure as many people as standard care while sparing some from chemotherapy side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer triple-positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • 2nd Affiliated Hospital, School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310009, China

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ningbo No. 2 Hospital

    RECRUITING

    Ningbo, Zhejiang, 315010, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The First Affiliated Hospital of Nanjing Medical University

    RECRUITING

    Nanjing, Jiangsu, 210029, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact